Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 382

1.

Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options.

Worswick S, Cotliar J.

Dermatol Ther. 2011 Mar-Apr;24(2):207-18. doi: 10.1111/j.1529-8019.2011.01396.x. Review.

PMID:
21410610
2.

An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.

Koh MJ, Tay YK.

Curr Opin Pediatr. 2009 Aug;21(4):505-10. doi: 10.1097/MOP.0b013e32832d1fef. Review.

PMID:
19474732
3.

Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.

Sane SP, Bhatt AD.

J Assoc Physicians India. 2000 Oct;48(10):999-1003. Review.

PMID:
11200928
4.

A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children.

Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ.

J Popul Ther Clin Pharmacol. 2011;18:e121-33. Epub 2011 Mar 21. Review.

PMID:
21467603
5.

[Analysis of treatments and deceased cases of severe adverse drug reactions--analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis].

Yamane Y, Aihara M, Tatewaki S, Matsukura S, Kanbara T, Yamakawa Y, Ikezawa Z.

Arerugi. 2009 May;58(5):537-47. Japanese.

PMID:
19487835
6.

High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.

Chen J, Wang B, Zeng Y, Xu H.

Eur J Dermatol. 2010 Nov-Dec;20(6):743-7. doi: 10.1684/ejd.2010.1077. Epub 2010 Oct 15.

PMID:
20952352
7.
8.

Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.

French LE, Trent JT, Kerdel FA.

Int Immunopharmacol. 2006 Apr;6(4):543-9. Epub 2005 Dec 19. Review.

PMID:
16504917
9.

[Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].

Halevy S.

Harefuah. 2010 Mar;149(3):186-90, 193. Review. Hebrew.

PMID:
20684173
10.

Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Wong KC, Kennedy PJ, Lee S.

Australas J Dermatol. 1999 Aug;40(3):131-4.

PMID:
10439522
11.
12.

Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options.

Teo L, Tay YK, Liu TT, Kwok C.

Singapore Med J. 2009 Jan;50(1):29-33. Review. Erratum in: Singapore Med J. 2012 Mar;53(3):220. Dosage error in article text.

13.

Stevens-Johnson syndrome and toxic epidermal necrolysis.

Parrillo SJ.

Curr Allergy Asthma Rep. 2007 Jul;7(4):243-7. Review.

PMID:
17547844
14.

The ophthalmologist's role in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis.

Fu Y, Gregory DG, Sippel KC, Bouchard CS, Tseng SC.

Ocul Surf. 2010 Oct;8(4):193-203.

PMID:
20964982
15.

Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome.

Mittmann N, Chan B, Knowles S, Cosentino L, Shear N.

Am J Clin Dermatol. 2006;7(6):359-68. Review.

PMID:
17173470
16.

Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.

Khalili B, Bahna SL.

Ann Allergy Asthma Immunol. 2006 Sep;97(3):272-80; quiz 281-3, 320. Review.

PMID:
17042130
17.

Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children.

Koh MJ, Tay YK.

J Am Acad Dermatol. 2010 Jan;62(1):54-60. doi: 10.1016/j.jaad.2009.06.085. Epub 2009 Oct 7.

PMID:
19811851
18.

Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.

Abe R.

J Dermatol Sci. 2008 Dec;52(3):151-9. doi: 10.1016/j.jdermsci.2008.06.003. Epub 2008 Jul 26. Review.

PMID:
18657400
19.

Severe cutaneous adverse reactions to drugs.

Chia FL, Leong KP.

Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):304-9. Review.

PMID:
17620821
20.

Supplemental Content

Support Center